Breaking News Instant updates and real-time market news.

AGEN

Agenus

$4.35

-0.1 (-2.25%)

, INCY

Incyte

$105.07

-0.1 (-0.10%)

08:53
11/30/16
11/30
08:53
11/30/16
08:53

Agenus begins Phase 1/2 trial of anti-OX40 agonist antibody for solid tumors

Agenus (AGEN) has dosed the first patient in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, and in collaboration with, Incyte (INCY). The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1949 in patients with advanced or metastatic solid tumors and determine its pharmacologically active and/or maximum tolerated dose. Part 2 of the trial is planned to evaluate the recommended dose of INCAGN1949 in multiple tumor types.

AGEN

Agenus

$4.35

-0.1 (-2.25%)

INCY

Incyte

$105.07

-0.1 (-0.10%)

  • 03

    Dec

  • 04

    Dec

AGEN Agenus
$4.35

-0.1 (-2.25%)

10/28/16
HCWC
10/28/16
DOWNGRADE
Target $5
HCWC
Neutral
Agenus downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Agenus to Neutral saying any significant clinical results are at least 12-18 months away. The analyst expects the stock to be range bound given a lack of catalysts. He cut his price target for the shares to $5 from $10.
03/11/16
MAXM
03/11/16
UPGRADE
Target $7
MAXM
Buy
Agenus upgraded to Buy from Hold at Maxim
12/16/15
12/16/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abeona Therapeutics (ABEO) initiated with a Buy at Maxim... Accelerate Diagnostics (AXDX) initiated with an Overweight at Piper Jaffray... Aetna (AET) initiated with a Neutral at Credit Suisse... Agenus (AGEN) initiated with a Buy at Jefferies... Apple Hospitality REIT (APLE) initiated with a Buy at Canaccord... Brunswick (BC) initiated with an Overweight at JPMorgan... Carlisle (CSL) initiated with a Buy at Wunderlich... Castlight Health (CSLT) initiated with a Buy at Topeka... Centene (CNC) initiated with an Outperform at Credit Suisse... ConAgra (CAG) initiated with a Buy at Jefferies... Dean Foods (DF) initiated with a Buy at Jefferies... First Merchants (FRME) initiated with a Neutral at SunTrust... Flowers Foods (FLO) initiated with a Buy at Jefferies... Glatfelter (GLT) initiated with a Buy at Sidoti... HCA Holdings (HCA) initiated with an Outperform at Credit Suisse... Hain Celestial (HAIN) assumed with a Buy at Jefferies... Hormel Foods (HRL) initiated with a Buy at Jefferies... Humana (HUM) initiated with a Neutral at Credit Suisse... Ingredion (INGR) initiated with a Buy at Jefferies... J & J Snack Foods (JJSF) initiated with a Hold at Jefferies... J.M. Smucker (SJM) initiated with a Buy at Jefferies... Kura Oncology (KURA) initiated with a Buy at Citi... LifePoint (LPNT) initiated with an Outperform at Credit Suisse... MasterCard (MA) initiated with a Buy at UBS... Matador (MTDR) initiated with a Neutral at BofA/Merrill... McCormick (MKC) initiated with a Hold at Jefferies... Molina Healthcare (MOH) initiated with a Neutral at Credit Suisse... NetApp (NTAP) initiated with an Underperform at JMP Securities... Nimble Storage (NMBL) initiated with a Market Perform at JMP Securities... Pilgrim's Pride (PPC) initiated with a Hold at Jefferies... Pure Storage (PSTG) initiated with an Outperform at JMP Securities... Rexford Industrial (REXR) initiated with a Buy at Stifel... Rice Energy (RICE) initiated with a Hold at Deutsche Bank... Sanderson Farms (SAFM) initiated with an Underperform at Jefferies... Snyder's-Lance (LNCE) initiated with a Buy at Jefferies... SodaStream (SODA) initiated with a Hold at Jefferies... Tenet (THC) initiated with a Neutral at Credit Suisse... TreeHouse (THS) initiated with a Buy at Jefferies... Tyson Foods (TSN) initiated with a Buy at Jefferies... UnitedHealth (UNH) initiated with an Outperform at Credit Suisse... Universal Health (UHS) initiated with a Neutral at Credit Suisse... Varonis (VRNS) initiated with a Buy at Lake Street... Visa (V) initiated with a Buy at UBS... WellCare (WCG) initiated with an Underperform at Credit Suisse... WhiteWave (WWAV) initiated with a Buy at Jefferies... aTyr Pharma (LIFE) initiated with a Neutral at Citi.
12/16/15
JEFF
12/16/15
INITIATION
Target $8
JEFF
Buy
Agenus initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Agenus with a Buy rating and $8 price target.
INCY Incyte
$105.07

-0.1 (-0.10%)

11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
11/18/16
RHCO
11/18/16
NO CHANGE
RHCO
Incyte has several positive catalysts, says SunTrust
SunTrust analyst PEter Lawson says he expects Incyte's baricitinib, which he calls a key profitability driver for the company, to be approved by the FDA next quarter. He also expects the company to benefit from positive data on its epacadostat and IOs in solid tumor settings. The analyst keeps a Buy rating on the shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.

TODAY'S FREE FLY STORIES

HZNP

Horizon Pharma

$19.39

-0.82 (-4.06%)

06:57
12/08/16
12/08
06:57
12/08/16
06:57
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 14

    Dec

BLK

BlackRock

$377.52

5.84 (1.57%)

06:56
12/08/16
12/08
06:56
12/08/16
06:56
Periodicals
BlackRock signs preliminary deal to move to Manhattan's West Side, WSJ says »

BlackRock has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$9.56

0.11 (1.16%)

06:56
12/08/16
12/08
06:56
12/08/16
06:56
Upgrade
AMD rating change  »

AMD upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVHC

Envision Healthcare

$69.19

-2.51 (-3.50%)

06:55
12/08/16
12/08
06:55
12/08/16
06:55
Initiation
Envision Healthcare initiated  »

Envision Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:55
12/08/16
12/08
06:55
12/08/16
06:55
General news
NYMEX crude is showing a 0.8% gain »

NYMEX crude is showing a…

MEI

Methode Electronics

$39.00

0.45 (1.17%)

06:54
12/08/16
12/08
06:54
12/08/16
06:54
Earnings
Methode Electronics raises FY17 EPS view to $2.30-$2.45 from $2.11-$2.35 »

Consensus for FY17 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

IGT

International Game

$25.49

0.36 (1.43%)

, SNE

Sony

$28.61

0.45 (1.60%)

06:54
12/08/16
12/08
06:54
12/08/16
06:54
Hot Stocks
International Game signs license agreement with Sony Pictures Television »

International Game…

IGT

International Game

$25.49

0.36 (1.43%)

SNE

Sony

$28.61

0.45 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEI

Methode Electronics

$39.00

0.45 (1.17%)

06:53
12/08/16
12/08
06:53
12/08/16
06:53
Earnings
Methode Electronics reports Q2 EPS 66c, consensus 55c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

VRNT

Verint

$38.30

0.1 (0.26%)

06:52
12/08/16
12/08
06:52
12/08/16
06:52
Recommendations
Verint analyst commentary  »

Verint removed from Focus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AMC

AMC Entertainment

$32.65

-1.15 (-3.40%)

, CKEC

Carmike Cinemas

$33.45

-0.4 (-1.18%)

06:49
12/08/16
12/08
06:49
12/08/16
06:49
Hot Stocks
AMC Entertainment and Carmike Cinemas announce election deadline »

AMC Theatres (AMC) and…

AMC

AMC Entertainment

$32.65

-1.15 (-3.40%)

CKEC

Carmike Cinemas

$33.45

-0.4 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCBFF

Standard Chartered

$8.68

0.28 (3.33%)

06:47
12/08/16
12/08
06:47
12/08/16
06:47
Periodicals
StanChart sanctions investigation nearing completion, Bloomberg reports »

U.S. investigators have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$80.86

0.94 (1.18%)

06:46
12/08/16
12/08
06:46
12/08/16
06:46
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

lululemon

$59.84

2.6 (4.54%)

06:45
12/08/16
12/08
06:45
12/08/16
06:45
Upgrade
lululemon rating change  »

lululemon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

PRGO

Perrigo

$83.94

-0.53 (-0.63%)

06:44
12/08/16
12/08
06:44
12/08/16
06:44
Hot Stocks
Perrigo announces portfolio review developments, intends to restructure BCH unit »

Perrigo announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEB

CEB

$59.50

0.35 (0.59%)

06:43
12/08/16
12/08
06:43
12/08/16
06:43
Downgrade
CEB rating change  »

CEB downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHS

Universal Health

$111.36

-15.01 (-11.88%)

06:42
12/08/16
12/08
06:42
12/08/16
06:42
Hot Stocks
Universal Health issues statement on recent BuzzFeed article »

Universal Health issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

, GOOG

Alphabet

$771.19

12.08 (1.59%)

06:42
12/08/16
12/08
06:42
12/08/16
06:42
Recommendations
Alphabet Class A, Alphabet, Facebook, Amazon.com analyst commentary  »

Citi replaces Amazon with…

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

GOOG

Alphabet

$771.19

12.08 (1.59%)

FB

Facebook

$117.95

0.64 (0.55%)

AMZN

Amazon.com

$770.42

5.7 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

SMG

Scotts Miracle-Gro

$92.84

2.01 (2.21%)

06:41
12/08/16
12/08
06:41
12/08/16
06:41
Upgrade
Scotts Miracle-Gro rating change  »

Scotts Miracle-Gro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARAY

Accuray

06:40
12/08/16
12/08
06:40
12/08/16
06:40
Hot Stocks
Accuray reports first patients treated with new Radixact system »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TAX

Liberty Tax

$13.35

0.5 (3.89%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Earnings
Liberty Tax reports Q2 EPS (72c), consensus (71c) »

Reports Q2 revenue $7.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ZEN

Zendesk

$21.15

-0.02 (-0.09%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Conference/Events
Zendesk management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AMZN

Amazon.com

$770.42

5.7 (0.75%)

06:38
12/08/16
12/08
06:38
12/08/16
06:38
Periodicals
Amazon seeks to help publishers profit more from ads, WSJ says »

Amazon is advancing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFN

Infinera

$8.48

0.01 (0.12%)

06:37
12/08/16
12/08
06:37
12/08/16
06:37
Conference/Events
Infinera management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LLL

L-3 Communications

$161.56

3.1 (1.96%)

06:36
12/08/16
12/08
06:36
12/08/16
06:36
Downgrade
L-3 Communications rating change  »

L-3 Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLL

Ball Corp.

$75.58

1.38 (1.86%)

06:34
12/08/16
12/08
06:34
12/08/16
06:34
Recommendations
Ball Corp. analyst commentary  »

Ball Corp. recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.